Eagle IP to Attend INTA 2026 Annual Meeting in London

2 May 2026

We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be traveling to London from May 2 to May 6, 2026 in conjunction with the International Trademark Association (INTA) 2026 Annual Meeting..

If you or your team will be attending INTA2026 or will be in London during the first week of May, Jennifer would welcome the opportunity to meet for a coffee or a scheduled briefing. Please contact us to coordinate a time during the conference week.

Our Past Events

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

16 June 2026

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

5 June 2026

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2 June 2026

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

8 May 2026

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

8 May 2026

Eagle IP’s Jennifer Che to Attend LSPN North America Spring 2026 in Boston

29 April 2026

Recommended Insights

Can Post Filing Data Overcome Inventive Step in China?

19 November 2018

Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

What is the difference between an Invention Patent and a Utility Model Patent?

13 August 2021

There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

12 November 2018

Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

10 March 2025

An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]